Efficacy and safety of ropeginterferon in myeloproliferative neoplasms: a systematic review and meta-analysis
Authors:
Open Access
- 23 September 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1841557
Abstract
Background: Ropeginterferon alfa-2b (ropegIFN-α2b or ropeginterferon) has emerged as a therapeutic option for patients with myeloproliferative neoplasms, particularly polycythemia vera (PV), with potential disease-modifying effects. This systematic review aimed to evaluate the efficacy and safety of ropeginterferon across clinical and real-world studies. Methods: A systematic search of PubMed, Embase, and Web of Science was conducted to identify studies reporting clinical outcomes of ropeginterferon in patients with MPNs. An additional PubMed search was performed to capture recently published studies. Eligible studies were screened according to predefined inclusion criteria. Data on hematologic, molecular, clinical, and safety outcomes were extracted and narratively synthesized. A proportional meta-analysis was conducted for selected outcomes, including complete hematologic response (CHR), partial molecular response (PMR), and grade ≥3 cytopenias. Results: A total of 18 studies involving 1,836 patients were included. Pooled analysis demonstrated that CHR rates increased over time, from 26% at 3 months to 59% at 12 months, with an overall pooled estimate of 56% (95% CI: 46%–66%). PMR was achieved in 37% of patients (95% CI: 20%–59%), although with substantial heterogeneity. Molecular responses were supported by consistent reductions in JAK2 allele burden across studies. Clinical outcomes showed improvements in spleen size and symptom burden in several cohorts. Ropeginterferon was generally well tolerated. The pooled proportion of grade ≥3 cytopenias was 3% (95% CI: 1%–10%), and severe hepatotoxicity was uncommon, typically occurring in ≤5% of patients. Most adverse events were low grade, with infrequent treatment discontinuations. Conclusion: RopegIFN-α2b demonstrates favorable efficacy and safety profiles in patients with MPNs, especially in PV, with evidence of progressive hematologic and molecular responses over time. These findings support its role as a potentially disease-modifying therapy, although further standardized and long-term studies, focusing on ET and MF, are needed. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261337306 , identifier CRD420261337306.Keywords
Funding Information
- AOP Health
This publication has 46 references indexed in Scilit:
- A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) databaseAnnals of Hematology, 2025
- Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With RuxolitinibeJHaem, 2025
- Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective studyInternational Journal of Cancer, 2025
- Diagnosis and Treatment of Polycythemia VeraJAMA, 2025
- Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomesAnnals of Hematology, 2024
- Treatment outcome and germline predictive factors of ropeginterferon alpha‐2b in myeloproliferative neoplasm patientsCancer Medicine, 2024
- Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomesAnnals of Hematology, 2023
- Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Meta-Analysis with R2015
- Treating cancer with PEG IntronCancer, 2002